Heart diseases remain one of the leading causes of illnesses and death worldwide, despite decades of medical advancements. New medicines, devices, and treatment strategies continue to emerge, but behind every advancement lies a long and complex process of clinical research. ... Read this blog
Scientific organizations today have access to more data than ever before. Yet despite this abundance, scientific engagement often feels fragmented and reactive. ... Read this blog
Product launches unfold under immense pressure. Timelines are accelerated, expectations are high, and early perceptions can shape a product’s trajectory for years to come. In this context, teams cannot afford to rely on broad KOL (Key Opinion Leader) lists. ... Read this blog
As CNS healthcare professionals increasingly adopt digital channels for learning, collaboration, and sharing perspectives, engagement strategies must evolve in parallel. ... Read this blog
Field teams are under immense pressure to cover more HCPs with fewer resources. Territories that once made sense on spreadsheets quickly become misaligned with market dynamics as new specialists emerge or referral patterns shift, leading to uneven engagement. ... Read this blog
Cardiology clinical trials are among the most complex in medicine, spanning multicenter, multinational sites and involving a range of subspecialties, from interventional cardiology to heart failure, electrophysiology, and structural heart disease. ... Read this blog
Insights shared by Digital Opinion Leaders (DOLs) on social media often reflect their sentiments and perspectives on new research findings, evolving standards of care, and breakthroughs in their therapeutic domain. ... Read this blog
In biotech companies, the success of a new therapy depends not only on clinical efficacy but also on how effectively you engage key opinion leaders (KOLs). Ultimately, they are the ones who will adopt it in clinical practice and champion it on podiums and among peers. ... Read this blog
With the rise of new therapies, evolving treatment guidelines, and a growing number of healthcare professionals, ensuring that Medical Science Liaison (MSL) efforts are strategically focused is more important than ever. ... Read this blog
Engaging with Key Opinion Leaders (KOLs) can be a competitive advantage for pharmaceutical teams. From accelerating the drug development process to shaping market perceptions, KOLs are a critical part of the ecosystem. ... Read this blog
Launching a new cardiology product is no small feat. It’s a journey that demands precision, collaboration, and a deep understanding of the science behind them and the market. ... Read this blog
In Medical Affairs, timing is everything. Engaging a key opinion leader (KOL) too late after their priorities have shifted can mean missed opportunities. Static expert lists may once have sufficed, but they no longer reflect the pace of today’s influence landscape.
... Read this blog
Recommended
